Tharimmune has announced the filing of a prospectus supplement for an at-the-market offering agreement with Rodman & Renshaw LLC, acting as the sales agent. The offering allows Tharimmune to sell shares of its common stock, with an aggregate offering price of up to $1.65 million. The common stock is listed on The Nasdaq Capital Market under the symbol 'THAR.' The last reported sale price of Tharimmune's common stock was $5.17 per share as of June 5, 2024. The sales agent will receive a fixed commission rate of 3.0% of the gross offering proceeds. This move is part of Tharimmune's efforts to raise capital, with the sales potentially being made by any method permitted by law and deemed to be an 'at the market offering.' The date of the prospectus supplement is June 7, 2024.

Tharimmune has announced the filing of a prospectus supplement for an at-the-market offering agreement with Rodman & Renshaw LLC, acting as the sales agent. The offering allows Tharimmune to sell shares of its common stock, with an aggregate offering price of up to $1.65 million. The common stock is listed on The Nasdaq Capital Market under the symbol 'THAR.' The last reported sale price of Tharimmune's common stock was $5.17 per share as of June 5, 2024. The sales agent will receive a fixed commission rate of 3.0% of the gross offering proceeds. This move is part of Tharimmune's efforts to raise capital, with the sales potentially being made by any method permitted by law and deemed to be an 'at the market offering.' The date of the prospectus supplement is June 7, 2024.